Amyloidosis trials in Canada

In Canada 11 Also abroad 184

11 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Calgary, Montreal, Toronto, Vancouver
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Calgary, Greater Sudbury, Halifax, Hamilton, Kitchener, London, Mississauga, Ottawa, Québec, Rimouski, Scarborough Village, Toronto, Vancouver
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Calgary, London, Toronto, Vancouver
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Vancouver
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Where
Halifax, London, Montreal, Rimouski, Toronto, Vancouver
Age
18 years to 130 years
People
1,850 worldwide
Run by
AstraZeneca
See details and how to joinNCT06465810
No phaseTaking people
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Where
Vancouver
Age
18 years and over
People
320 worldwide
Run by
AstraZeneca
See details and how to joinNCT07654855
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Calgary
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
Phase 3Not yet taking people in Canada
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Calgary, Chicoutimi, London, Montr Al, Rimouski, Winnipeg
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Calgary, Toronto, Vancouver
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 1/2Taking people
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Where
Calgary, Toronto
Age
18 years and over
People
91 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07081646
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Calgary, London, Montreal, Rimouski, Toronto, Vancouver
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493